Giga Metals appoints Steven Latimer to its board of directors

Giga Metals Corp. (TSX-V: GIGA; OTCQB: GIGGF; FSE: BRR2) has appointed Steven Latimer as an independent director, effective July 8, 2026, according to a press release from the Vancouver-based mining company.

Latimer brings over 30 years of capital markets and investment banking experience in the global mining and metals sector. He currently serves as Managing Director and Head of North America at Bacchus Capital, a London-based mining-focused investment and merchant bank.

His previous roles include Interim CEO and Director of BG Gold, and Non-Executive Chairman of Alta Copper, a TSX Venture Exchange-listed Peruvian copper developer that was acquired by Fortescue Minerals. He also founded Jefferies' investment banking practice in Canada in 2012, where he served as Managing Director and Head of Canadian Investment Banking. Earlier positions included leadership roles at Credit Suisse and UBS Securities in Canada. He began his career in 1990 at Goldman Sachs in New York.

Latimer holds an MBA from the Kellogg School of Management at Northwestern University and an HBA from the Ivey Business School at Western University, along with CFA and ICD.D designations.

In connection with the appointment, Giga Metals has issued Latimer 550,000 stock options exercisable at $0.10 per share for a period of five years. One quarter of the options vest immediately, with an additional one quarter vesting annually. All options vest upon a change of control.

Giga Metals' core asset is the Turnagain Project in northern British Columbia, which the company describes as containing one of the few significant undeveloped sulfide nickel and cobalt resources in the world. The project is held through Hard Creek Nickel, a subsidiary jointly owned by Giga Metals and Mitsubishi Corporation.

You May Also Be Interested In

• Lithium Africa nominates two directors ahead of August AGM
• Altai Resources names Allister Avard to its board of directors
• Paulo Fontoura resigns from Lakefront Biotherapeutics board